Menu
Back to Journals » Lung Cancer: Targets and Therapy » Volume 13
Commentary
Deconstructing ADAURA: It is Time to Forgo Adjuvant Platinum-Based Chemotherapy in Resected IB-IIIA EGFR+ NSCLC (Except with RB Alterations?) When Adopting Adjuvant Osimertinib
| Total article views | HTML views | PDF downloads | Totals | ||
|---|---|---|---|---|---|
| 8,274 | Dovepress* | 7,212+ | 332 | 7,544 | |
| PubMed Central* | 1,062 | 267 | 1,329 | ||
| Totals | 8,274 | 599 | 8,873 | ||
| *Since 26 April 2022 | |||||
| Total mentioned | Delicious | Others | |||
|---|---|---|---|---|---|
| 16 | 0 | 0 | 1 | 7 | 8 |
View citations on PubMed Central and Google Scholar